Genentech isn’t currently developing a SARS-CoV-2 vaccine or therapeutic, but the biotech has been conducting research that could bring insight to bear on the willingness among communities of color to engage in clinical trials for COVID-19 vaccines and treatments. Quita Highsmith, Genentech’s chief diversity officer, speaks about that, and the biotech’s own efforts to recruit and instill more trust among underserved and medically disenfranchised patients.